{"id":"W2415009490","doi":"10.1177/135965350501000801","title":"TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i>","year":2005,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pharmacology; Drug; Protease inhibitor (pharmacology); CCR5 receptor antagonist; In vitro; Medicine; Human immunodeficiency virus (HIV); Chemistry; Internal medicine; Antiretroviral therapy; Virology; Viral load; Inflammation; Chemokine receptor; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001986872,0.0008809167,0.00124188,0.0006160339,0.000185639,0.0001609394,0.0002420131,0.0003610063,0.0003187656],"category_scores_gemma":[0.000009238672,0.0006347836,0.0003363148,0.000554412,0.000212129,0.0003767439,0.00003885811,0.001809066,0.000445788],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003186268,"about_ca_system_score_gemma":0.0003701154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002979829,"about_ca_topic_score_gemma":0.0001100567,"domain_scores_codex":[0.9967985,0.0001056754,0.0006401012,0.0008946872,0.0006758728,0.0008852182],"domain_scores_gemma":[0.9987049,0.000132787,0.0003178984,0.0006528814,0.0001033606,0.00008820571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001407986,0.001475645,0.01000766,0.00009317315,0.001051421,0.001089746,0.001172533,7.163567e-7,0.03397018,0.000009365153,0.9345224,0.01519912],"study_design_scores_gemma":[0.006776081,0.000185881,0.0003447579,0.0006726192,0.0001137123,0.00009584278,0.00006977349,0.0000133391,0.04243564,0.000009959896,0.948589,0.0006933679],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.1059144,0.002090728,0.000146117,0.8659341,0.0007117438,0.00264757,0.0002308971,0.0003841169,0.02194032],"genre_scores_gemma":[0.1507084,0.001434438,0.007045964,0.4309372,0.005887589,0.0003775571,0.001328267,0.0005217868,0.4017588],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.434997,"threshold_uncertainty_score":0.9996104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03081082085888891,"score_gpt":0.2673798028364486,"score_spread":0.2365689819775597,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}